Association of Peritumoral Radiomics With Tumor Biology and Pathologic Response to Preoperative Targeted Therapy for HER2 (ERBB2)–Positive Breast Cancer-Reference-Cited by-同舟云学术

Association of Peritumoral Radiomics With Tumor Biology and Pathologic Response to Preoperative Targeted Therapy for HER2 (ERBB2)–Positive Breast Cancer

Published:2019-04-19 Issue:4 Volume:2 Page:e192561
ISSN:2574-3805
Container-title:JAMA Network Open
language:en
Short-container-title:JAMA Netw Open

Author:

Braman Nathaniel¹,Prasanna Prateek¹,Whitney Jon¹,Singh Salendra²,Beig Niha¹,Etesami Maryam³,Bates David D. B.⁴,Gallagher Katherine⁴,Bloch B. Nicolas⁵⁶,Vulchi Manasa⁷,Turk Paulette⁸,Bera Kaustav¹,Abraham Jame⁷,Sikov William M.⁹,Somlo George¹⁰¹¹,Harris Lyndsay N.²¹²,Gilmore Hannah¹³,Plecha Donna¹⁴,Varadan Vinay²,Madabhushi Anant¹¹⁵

Affiliation:

1. Department of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio

2. Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio

3. Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, Connecticut

4. Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York

5. Department of Radiology, Boston Medical Center, Boston, Massachusetts

6. Department of Radiology, Boston University School of Medicine, Boston, Massachusetts

7. Department of Hematology and Medical Oncology, The Cleveland Clinic, Cleveland, Ohio

8. Department of Diagnostic Radiology, The Cleveland Clinic, Cleveland, Ohio

9. Program in Women’s Oncology, Women and Infants Hospital, Warren Alpert Medical School of Brown University, Providence, Rhode Island

10. Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, California

11. Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California

12. National Cancer Institute, National Institutes of Health, Bethesda, Maryland

13. Department of Pathology, University Hospitals Cleveland Medical Center, Cleveland, Ohio

14. Department of Radiology, University Hospitals Cleveland Medical Center, Cleveland, Ohio

15. Louis Stokes Cleveland Veterans Administration Medical Center, Cleveland, Ohio

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

http:///jamanetworkopen/article-pdf/2/4/e192561/17478497/braman_2019_oi_190112.pdf

Reference74 articles.

1. Trastuzumab: updated mechanisms of action and resistance in breast cancer.;Vu;Front Oncol,2012

2. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer.;Nahta;Nat Clin Pract Oncol,2006

3. Research-based PAM50 subtype predictor identifies higher responses and improved survival outcomes in HER2-positive breast cancer in the NOAH study.;Prat;Clin Cancer Res,2014

4. Immune signatures following single dose trastuzumab predict pathologic response to preoperative trastuzumab and chemotherapy in HER2-positive early breast cancer.;Varadan;Clin Cancer Res,2016

5. Deconstructing the molecular portraits of breast cancer.;Prat;Mol Oncol,2011

Cited by 217 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multicenter radio-multiomic analysis for predicting breast cancer outcome and unravelling imaging-biological connection;npj Precision Oncology;2024-09-07

2. The longitudinal changes in multiparametric MRI during neoadjuvant chemotherapy can predict treatment response early in patients with HER2-positive breast cancer;European Journal of Radiology;2024-09

3. Assessing the stability and discriminative ability of radiomics features in the tumor microenvironment: Leveraging peri-tumoral regions in vestibular schwannoma;European Journal of Radiology;2024-09

4. A comprehensive approach for evaluating lymphovascular invasion in invasive breast cancer: Leveraging multimodal MRI findings, radiomics, and deep learning analysis of intra- and peritumoral regions;Computerized Medical Imaging and Graphics;2024-09

5. Peri-Tumoural Lipid Composition and Hypoxia for Early Immune Response to Neoadjuvant Chemotherapy in Breast Cancer;International Journal of Molecular Sciences;2024-08-28